Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.
| Revenue (TTM) | $596.96M |
| Gross Profit (TTM) | $501.66M |
| EBITDA | $305.83M |
| Operating Margin | 49.00% |
| Return on Equity | 24.50% |
| Return on Assets | 16.30% |
| Revenue/Share (TTM) | $4.87 |
| Book Value | $8.29 |
| Price-to-Book | 3.81 |
| Price-to-Sales (TTM) | 6.46 |
| EV/Revenue | 5.2 |
| EV/EBITDA | 10.14 |
| Quarterly Earnings Growth (YoY) | 11.10% |
| Quarterly Revenue Growth (YoY) | 5.60% |
| Shares Outstanding | $122.42M |
| Float | $115.58M |
| % Insiders | 5.57% |
| % Institutions | 90.00% |
Volatility is currently contracting
Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals in a $4.1 billion deal involving Italian state lender CDP.
The Italian pharma company grows its presence in the U.S. market and strengthens its global leadership in Brain Health and Rare Diseases Completion of the transaction gives Angelini Pharma ownership of Catalyst's product portfolio The transaction is being carried out with the participation of funds managed by Blackstone CDP Equity approves €1 billion investment in Angelini Pharma Italy remains a strategic production and scientific hub ROME and CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Angelini Pharma S.p.A.
Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led t.
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks presents investors with the better value opportunity right now?
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CPRX and any ticker you trade — then tracks every position and per-strategy win rate.
